Drug delivery technologies have enabled the development of many pharmaceutical products that improve patient health by enhancing the delivery of a therapeutic to its target site, minimizing off-target accumulat
All authors are or have been employees of Alnylam Pharmaceuticals during the writing of the manuscript and report ownership of equity in Alnylam Pharmaceuticals: V.J. is chief technology officer; A.V. is chief innovation officer; K.F. is chief scientific officer; and M.A.M. is senior vice...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 20, 2025--Alnylam Pharmaceuticals, Inc.(Nasdaq: ALNY), the leading RNAi therapeutics company, today announced theU.S. Food and Drug Administration(FDA) approval of the supplemental New Drug Application (sNDA) for its RNAi therapeutic, AMVUTTRA®(vutr...
requires an exquisite degree of control — creating the need for Local delivery different delivery vehicles and Alnylam focused on local deliv- potentially even specialized tar- ery when it began to develop geting strategies. Animal studies2 RNA-based therapeutics. Its have shown that it is ...
The armamentarium for the treatment of dyslipidemia today comprises six different modes of action with overall around 24 different drugs. The treatment of lipid disorders was revolutionized with the introduction of statins which have become the most impo
2. Common nanoparticles used in disease treatment and diagnostics 3. Advancements in the clinical application of cancer nanomedicines 4. Challenges and countermeasures in translating cancer nanomedicine from the bench to the bedside 5. Case studies and practical applications 6. Future opportunities in can...
Future applications of the model are also explored. Background This review aims to describe the Human Viral Challenge model; its history, its utility and specifically how it has recently been, and can be used, to potentially accelerate the development of novel therapies for the unmet medical need...
On AWS, Ultima is creating a cost-effective solution for the future. One of its customers is using the UG 100 to run variant calling on thousands of genomes to build a large-scale genetic database. “With our technology, we are bringing sequencing costs down to a fraction of what they ...
The PCSK9 inhibitor market is projected to experience substantial growth due to its use in statin-intolerant patients, emerging strategies for PCSK9 inhibition, its potential applications across broader therapeutic a...
and RNA delivery for silencing of genes (patisiran, ONPATTRO®, Alnylam Pharmaceuticals, Cambridge, MA, USA) or for vaccination such as the RNA-based coronavirus disease 2019 (COVID-19) vaccines demonstrated the feasibility of using macromolecules inside cells for therapy. Chemical carriers are ...